Core Insights - Three stocks with strong momentum and buy rank are highlighted for investors: Nova Ltd., Freshworks Inc., and enGene Holdings Inc. [1][2][3] Group 1: Nova Ltd. (NVMI) - Nova Ltd. is a semiconductor equipment company with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings increased by 5.3% over the last 60 days [1] - Nova's shares gained 56.8% over the last three months, significantly outperforming the S&P 500's 3.5% increase [1] - The company has a Momentum Score of A [1] Group 2: Freshworks Inc. (FRSH) - Freshworks Inc. is a software development company with a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings increased by 6% over the last 60 days [2] - Freshworks' shares gained 15.2% over the last three months, also outperforming the S&P 500's 3.5% increase [2] - The company has a Momentum Score of A [2] Group 3: enGene Holdings Inc. (ENGN) - enGene Holdings Inc. is a clinical-stage biotechnology company with a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings increased by 8.7% over the last 60 days [3] - enGene Holdings' shares gained 13.5% over the last six months, slightly outperforming the S&P 500's 9.4% increase [3] - The company has a Momentum Score of B [3]

Group 1 - GE Aerospace (GE) has seen a 3.9% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Oportun Financial Corporation (OPRT) has experienced a 9.2% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - enGene Holdings Inc. (ENGN) has recorded an 8.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Freshworks Inc. (FRSH) has seen a 6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Nova Ltd. (NVMI) has experienced a 5.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2]

Financial Data and Key Metrics Changes - Engene is entering a market projected to grow significantly, with estimates suggesting a market size of upwards of $20 billion for non-muscle invasive bladder cancer (NMIBC) treatments [5][6] - The company has sufficient capital to execute its plans, with a runway projected into 2027 [6] Business Line Data and Key Metrics Changes - Engene's primary product, dedalimogene, is a non-viral genetic medicine designed for NMIBC, aiming to be the first choice for urologists [20][40] - The company is conducting a pivotal study (LEGEND) with a focus on BCG unresponsive NMIBC patients, with data updates expected in the second half of 2025 and a BLA filing anticipated in mid-2026 [25][39] Market Data and Key Metrics Changes - Bladder cancer represents a significant healthcare cost, with an estimated annual cost of $6.5 billion in the United States [8] - The treatment landscape for NMIBC is evolving, with a shift from surgical options to medical therapies, highlighting the unmet need for effective non-surgical treatments [11][43] Company Strategy and Development Direction - Engene aims to provide a non-surgical alternative to radical cystectomy, focusing on ease of use and accessibility for urologists in community clinics [12][40] - The company is positioning dedalimogene as a first-line treatment option, emphasizing its practical application in busy clinical settings [41][43] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming data updates and the potential for dedalimogene to meet the needs of high-risk NMIBC patients [56] - The company is aware of the competitive landscape and believes that its product profile will stand out due to its ease of use and favorable safety profile [54][56] Other Important Information - The LEGEND study is designed to demonstrate the efficacy of dedalimogene in various patient cohorts, including those with high-risk disease and those previously treated with BCG [25][51] - Recent protocol changes aim to align the study with current clinical practices, potentially enhancing patient outcomes [34][37] Q&A Session Summary Question: Impact of modified inclusion criteria on enrollment - Management expects the changes to be largely enrollment neutral, with potential benefits to overall enrollment due to the alignment with standard practices [45][46] Question: Cost advantages of dedalimogene compared to viral agents - The ease of use and lack of cold chain storage requirements for dedalimogene are significant advantages, allowing for more efficient patient management in busy clinics [47][50] Question: Utility of other cohorts in the study - Other cohorts are seen as opportunities to demonstrate dedalimogene's potential in real-world settings, with the goal of providing comprehensive data to support future use [51][52] Question: Investor perception and valuation - Management believes investors may be focused on the complete response rate, potentially overlooking the product's operational advantages and overall profile [54][56]

Core Viewpoint - enGene Holdings Inc. (ENGN) has seen an 8% increase in share price over the past four weeks, closing at $8.10, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $27.44, representing a 238.8% upside [1] Price Targets - The average price target consists of nine estimates ranging from a low of $16 to a high of $37, with a standard deviation of $7.38, indicating variability among analysts [2] - The lowest estimate suggests a 97.5% increase from the current price, while the highest estimate indicates a 356.8% upside [2] Analyst Sentiment - Analysts show a consensus that ENGN will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][10] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 8.5%, with three estimates moving higher and one lower [11] Zacks Rank - ENGN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [12]

Core Viewpoint - The recent upgrade of enGene Holdings Inc. to a Zacks Rank 1 (Strong Buy) reflects a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [5][6][7]. Earnings Estimates - For the fiscal year ending October 2025, enGene Holdings Inc. is expected to earn -$1.72 per share, representing a change of -17.8% from the previous year's reported number [4]. - Over the past three months, the Zacks Consensus Estimate for enGene Holdings Inc. has increased by 6.7% [9]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - The Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings across its universe of over 4000 stocks, ensuring that only the top 5% receive a 'Strong Buy' rating [10][12]. Institutional Investor Influence - Changes in earnings estimates are strongly correlated with near-term stock price movements, largely due to institutional investors who adjust their valuations based on these estimates [13][14]. - The upgrade of enGene Holdings Inc. to a Zacks Rank 1 positions it in the top 5% of Zacks-covered stocks, indicating potential for higher stock movement in the near term [17].

Company Overview - enGene Holdings (NASDAQ: ENGN) is a biotech company focused on developing gene therapies, particularly targeting specific forms of bladder cancer [1] - The company utilizes plasmid technology to advance its therapeutic approaches, aiming to demonstrate the efficacy of non-viral methods in treatment [1] Industry Insights - The biotech sector is increasingly exploring gene therapies as a viable treatment option for various cancers, indicating a growing trend towards innovative therapeutic solutions [1]

Group 1 - enGene Holdings Inc. (ENGN) has experienced a significant decline of 16.9% over the past four weeks, but it is now positioned for a potential trend reversal as it is in oversold territory [1] - The Relative Strength Index (RSI) for ENGN is currently at 26.43, indicating that the heavy selling pressure may be exhausting itself, suggesting a possible reversal in the stock's trend [4] - There is strong consensus among Wall Street analysts that ENGN will report better earnings than previously predicted, with a 2.3% increase in the consensus EPS estimate over the last 30 days [5] Group 2 - ENGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for price appreciation in the near term [5]

Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) remains on track with interim data anticipated in mid-2024 Closed a $200 million oversubscribed private financing, expected to extend cash runway into 2027 BOSTON and MONTREAL, March 11, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unre ...

Financing included participation from new and existing investors Pro forma cash and cash equivalents expected to fund current operating plan into 2027 BOSTON and MONTREAL, Feb. 14, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that it has agreed to sell 20 million of its common shares at a ...

Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70 BOSTON and MONTREAL, Jan. 30, 2024 /PRNewswire/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment ...